|
|
|
|
|
|
|
|
|
07.04.26 - 14:06
|
Life Sciences Ontario Welcomes New Board Members in 2026 Following Annual General Meeting (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--Life Sciences Ontario (LSO) is pleased to announce the appointment of four distinguished leaders to its Board of Directors, following its Annual General Meeting on March 25, 2026.
The newly appointed board members are:
Amelia Swanson, vice-president, Medtech Canada
Dave Smardon, president and CEO, Bioenterprise Canada
Leslie Madden, senior director, head of government affairs and policy, Moderna Canada
Melody Greaves, executive director and vice-president, government relations, Canadian Nuclear Isotope Council
“We are delighted to welcome such highly qualified professionals to the Board,” said Dr. Jason Field, president and CEO, Life Sciences Ontario. “They each bring exceptional experience and a demonstrated ability to drive innovation, shape policy, and build meaningful partnerships. We look forward to working together to advance Ontario's life sciences sector and strengthen its global competitiveness.”
During the Annual General Meeting, LSO also presented its 2025 Ann...
|
|
|
|
|
|
|
30.03.26 - 16:48
|
3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next (24/7 Wall St.)
|
|
|
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9% over the same period, still below its pandemic peak. Novavax (NASDAQ: NVAX) has lost 95.3% in five years. The central question for any investor holding or considering ... 3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next
The post 3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.03.26 - 19:03
|
Moderna: Zurück in der Spur (Der Aktionaer)
|
|
|
Mehrere positive Entwicklungen – von regulatorischen Fortschritten über eine Einigung in einem wichtigen Patentstreit bis hin zu Fortschritten in der Pipeline – sorgen für Aufbruchstimmung....
|
|
|
|
|
10.03.26 - 10:15
|
Moderna-Aktie +6%: Wie weit geht der Höhenflug noch? (Sharedeals)
|
|
|
Die Moderna-Aktie zaubert seit Jahresbeginn eine atemberaubende Performance von +80% aufs Börsenparket. Zum Wochenstart legt sie um +6% auf 55,74 US$ zu. Was steckt hinter diesem Höhenflug und kann er noch weitergehen? Rechtsstreit beigelegt Vor zehn Tagen ereilte den Markt eine sehr positive Nachricht des US-Biotech-Unternehmens, das für seine Covid-Impfstoffe bekanntgeworden ist: In einem Rechtsstreit […]
The post Moderna-Aktie +6%: Wie weit geht der Höhenflug noch? first appeared on sharedeals.de....
|
|
|
09.03.26 - 18:54
|
What′s Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga)
|
|
|
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
Latest Ratings for MRNA
DateFirmActionFromTo Mar 2022Deutsche BankMaintainsHold Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022SVB LeerinkMaintainsUnderperform
View More Analyst Ratings for MRNA
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
